CinnaGen Co. has founded in 1994 with the goal of manufacturing High-Tech products in biotechnology and related fields. Since its start of operations with 4 scientists, CinnaGen has grown to become the biggest Biopharma manufacturer and biotech exporter in the region. The concept was to be active in the research and development of new potent biotech-based products for covering regional market. Enzymes, molecular biology reagents and PCR kits are the first products and then CinnaGen use its proprietary set of technologies to endow Monoclonal Antibodies for blood group typing. The next important step for CinnaGen was the entry to the therapeutic recombinant protein area. Today the company prides itself in its innovative skills meeting today’s challenges. We focus our efforts on developing the biogenerics candidates in the areas of immunological diseases and oncology as well as providing contract research development services. The company is spending over 20 percent of its total turnover on R&D activities. CinnaGen is strategically positioned to become and remain leading biotechnology company in the region. Our aim is to use our expertise to identify and acquire selected products, through strategic partnerships to promote sustainable development in human health.
Looking for a particular CinnaGen employee's phone or email?
The CinnaGen annual revenue was $124.1 million in 2026.
Mehran Montajabi is the Vice President of CinnaGen.
430 people are employed at CinnaGen.
CinnaGen is based in Tehran, Tehran.
The NAICS codes for CinnaGen are [54, 5417, 54171, 541, 541713].
The SIC codes for CinnaGen are [873, 87].